Olpasiran is under clinical development by Amgen and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Olpasiran’s likelihood of approval (LoA) and phase transition for Atherosclerosis took place on 01 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Olpasiran Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Olpasiran (formerly known as AMG 890) is under development for the treatment of atherosclerosis. The drug candidate is administered subcutaneously in the form of solution. It is an RNAi therapeutic which acts by targeting apolipoprotein A. It is developed based on dynamic polyconjugate (DPC) delivery platform technology and TRiM technology.
Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in six focused disease areas including cardiovascular diseases, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels such as print, television and online media. Amgen is headquartered in Thousand Oaks, California, the US.
Quick View Olpasiran LOA Data
|Highest Development Stage|